Baicalein suppresses metastasis of breast cancer cells by inhibiting EMT via downregulation of SATB1 and Wnt/β-catenin pathway

Drug Design, Development and Therapy

Volumn 10, Issue , 2016, Pages 1419-1441

  Ma, Xing Cong ^a   Yan, Wanjun ^a   Dai, Zhijun ^a   Gao, Xiaoyan ^a   Ma, Yinan ^a   Xu, Quntao ^b   Jiang, Jiantao ^a   Zhang, Shuqun ^a  

^a THE SECOND AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b Henan Pingyuan Optics Electronics Co   (China)

Author keywords

Baicalein; Breast cancer; EMT; Metastasis; SATB1; Wnt catenin pathway

Indexed keywords

BAICALEIN; BETA CATENIN; BINDING PROTEIN; SPECIAL AT RICH SEQUENCE BINDING PROTEIN 1; UNCLASSIFIED DRUG; WNT PROTEIN; ANTINEOPLASTIC AGENT; FLAVANONE DERIVATIVE; MATRIX ATTACHMENT REGION BINDING PROTEIN; SATB1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INVASION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER METASTASIS; LOW DRUG DOSE; LUNG METASTASIS; METASTASIS INHIBITION; MIGRATION INHIBITION; MITOSIS INHIBITION; MOUSE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; BREAST NEOPLASMS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; METABOLISM; NEOPLASM METASTASIS; NUDE MOUSE; PATHOLOGY; STRUCTURE ACTIVITY RELATION; TUMOR CELL CULTURE; WNT SIGNALING PATHWAY; WOUND HEALING;

ANIMALS; ANTINEOPLASTIC AGENTS; BETA CATENIN; BREAST NEOPLASMS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FLAVANONES; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MATRIX ATTACHMENT REGION BINDING PROTEINS; MICE; MICE, NUDE; MOLECULAR STRUCTURE; NEOPLASM METASTASIS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; WNT SIGNALING PATHWAY; WOUND HEALING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84964561124     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S102541     Document Type: Article

References (61)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer. 2010;127(12):2893–2917.
2. Benson JR, Jatoi I. The global breast cancer burden. Future Oncol. 2012;8(6):697–702.
3. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.
4. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006;12(8):895–904.
5. Christofori G. New signals from the invasive front. Nature. 2006;441(7092):444–450.
6. Cai ST, Han HJ, Kohwi-Shigematsu T. Tissue-specific nuclear architecture and gene expression regulated by SATB1. Nat Genet. 2003;34(1):42–51.
7. Wen J, Huang SM, Rogers H, Dickinson LA, Kohwi-Shigematsu T, Noguchi CT. SATB1 family protein expressed during early erythroid differentiation modifies globin gene expression. Blood. 2005;105(8):3330–3339.
8. Alvarez JD, Yasui DH, Niida H, Joh T, Loh DY, Kohwi-Shigematsu T. The MAR-binding protein SATB1 orchestrates temporal and spatial expression of multiple genes during T-cell development. Genes Dev. 2000;14(5):521–535.
9. Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T. SATB1 reprograms gene expression to promote breast tumour growth and metastasis. Nature. 2008;452(7184):187–193.
10. Cheng C, Lu X, Wang G, et al. Expression of SATB1 and heparanase in gastric cancer and its relationship to clinicopathologic features. APMIS. 2010;118(11):855–863.
11. Lu X, Cheng C, Zhu S, et al. SATB1 is an independent prognostic marker for gastric cancer in a Chinese population. Oncol Rep. 2010;24(4):981–987.
12. Zhang J, Zhang B, Zhang X, et al. SATB1 expression is associated with biologic behavior in colorectal carcinoma in vitro and in vivo. PLoS One. 2013;8(1):e47902.
13. Tu W, Luo M, Wang Z, et al. Upregulation of SATB1 promotes tumor growth and metastasis in liver cancer. Liver Int. 2012;32(7):1064–1078.
14. Xiang J, Zhou L, Li S, et al. AT-rich sequence binding protein 1: contribution to tumor progression and metastasis of human ovarian carcinoma. Oncol Lett. 2012;3(4):865–870.
15. Nodin B, Hedner C, Uhlen M, Jirström K. Expression of the global regulator SATB1 is an independent factor of poor prognosis in high grade epithelial ovarian cancer. J Ovarian Res. 2012;5(1):24.
16. Shukla S, Sharma H, Abbas A, et al. Upregulation of SATB1 is associated with prostate cancer aggressiveness and disease progression. PLoS One. 2013;8(1):e53527.
17. Mao L, Yang C, Wang J, et al. SATB1 is overexpressed in metastatic prostate cancer and promotes prostate cancer cell growth and invasion. J Transl Med. 2013;11:111.
18. Han B, Luan L, Xu Z, Wu B. Expression and biological roles of SATB1 in human bladder cancer. Tumor Biol. 2013;34(5):2943–2949.
19. Gough NR. Focus issue: Wnt and β-catenin signaling in development and disease. Sci Signal. 2012;5(206):eg2.
20. Dickinson ME, McMahon AP. The role of Wnt genes in vertebrate development. Curr Opin Genet Dev. 1992;2(4):562–566.
21. Brennan KR, Brown AM. Wnt proteins in mammary development and cancer. J Mammary Gland Biol Neoplasia. 2004;9(2):119–131.
22. Howe LR, Brown AM. Wnt signaling and breast cancer. Cancer Biol Ther. 2004;3:36–41.
23. Kurayoshi M, Oue N, Yamamoto H, et al. Expression of Wnt-5 is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion. Cancer Res. 2006;66(21):10439–10448.
24. Gupta S, Iljin K, Sara H, et al. FZD4 as a mediator of ERG oncogene-induced Wnt signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res. 2010;70(17):6735–6745.
25. Kobune M, Chiba H, Kato J, et al. Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism. Mol Cancer Ther. 2007;6(6):1774–1784.
26. Lalli E, Wakil AE. The Wnt/β-catenin pathway in adrenocortical development and cancer. Mol Cell Endocrinol. 2010;332(1–2):32–37.
27. Notani D, Gottimukkala KP, Jayani RS, et al. Global regulator SATB1 recruits β-catenin and regulates TH2 differentiation in Wnt-dependent manner. PLoS Biol. 2010;8(1):e1000296.
28. Pidgeon GP, Kandouz M, Meram A, Honn KV. Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxygenase inhibition in prostate cancer cells. Cancer Res. 2002;62(9):2721–2727.
29. Lee HZ, Leung HW, Lai MY, Wu CH. Baicalein induced cell cycle arrest and apoptosis in human lung squamous carcinoma CH27 cells. Anticancer Res. 2005;25(2A):959–964.
30. Hyde CA, Missailidis S. Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumour-angiogenesis. Int Immunopharmacol. 2009;9:701–715.
31. Ling Y, Chen Y, Chen P, et al. Baicalein potently suppresses angiogenesis induced by vascular endothelial growth factor through the p53/Rb signaling pathway leading to G1/S cell cycle arrest. Exp Biol Med. 2011;236(7):851–858.
32. Eliza LZ, Agnieszka W, Zofia BO. Anticancer properties of Scutellaria baicalensis root in aspect of innate immunity regulation. Adv Clin Exp Med. 2010;19(4):419–428.
33. Chung H, Choi HS, Seo EK, Kang DH, Oh ES. Baicalin and baicalein inhibit transforming growth factor-β1-mediated epithelial-mesenchymal transition in human breast epithelial cells. Biochem Biophys Res Commun. 2015;458(3):707–713.
34. Prasad CP, Rath G, Mathur S, Bhatnagar D, Parshad R, Ralhan R. Expression analysis of E-cadherin, slug and GSK3β in invasive ductal carcinoma of breast. BMC Cancer. 2009;9:325.
35. Logullo AF, Nonogaki S, Pasini FS, Osório CA, Soares FA, Brentani MM. Concomitant expression of epithelial-mesenchymal transition biomarkers in breast ductal carcinoma: association with progression. Oncol Rep. 2010;23(2):313–320.
36. Lamb R, Ablett MP, Spence K, Landberg G, Sims AH, Clarke RB. Wnt pathway activity in breast cancer sub-types and stem-like cells. PLoS One. 2013;8(7):e67811.
37. Müller T, Bain G, Wang X, Papkoff J. Regulation of epithelial cell migration and tumor formation by β-catenin signaling. Exp Cell Res. 2002;208(1):119–133.
38. Wang L, Ling Y, Chen Y, et al. Flavonoid baicalein suppresses adhesion, migration and invasion of MDA-MB-231 human breast cancer cells. Cancer Lett. 2010;297:42–48.
39. Zheng YH, Yin LH, Grahn TH, Ye AF, Zhao YR, Zhang QY. Anticancer effects of baicalein on hepatocellular carcinoma cells. Phytother Res. 2014;28(9):1342–1348.
40. Yan X, Rui X, Zhang K. Baicalein inhibits the invasion of gastric cancer cells by suppressing the activity of the p38 signaling pathway. Oncol Rep. 2015;33(2):737–743.
41. Shang D, Li Z, Zhu Z, et al. Baicalein suppresses 17-β-estradiol-induced migration, adhesion and invasion of breast cancer cells via the G protein-coupled receptor 30 signaling pathway. Oncol Rep. 2015;33(4):2077–2085.
42. Zhang Z, Lv J, Lei X, et al. Baicalein reduces the invasion of glioma cells via reducing the activity of p38 signaling pathway. PLoS One. 2014;9(2):e90318.
43. Fingleton B. Matrix metalloproteinases: roles in cancer and metastasis. Front Biosci. 2006;11:479–491.
44. Nakayama Y, Mian IS, Kohwi-Shigematsu T, Ogawa T. A nuclear targeting determinant for SATB1, a genome organizer in the T cell lineage. Cell Cycle. 2005;4(8):1099–1106.
45. Iorns E, Hnatyszyn HJ, Seo P, Clarke J, Ward T, Lippman M. The role of SATB1 in breast cancer pathogenesis. J Natl Cancer Inst. 2010;102:1284–1296.
46. Han S, Xia J, Qin X, Han S, Wu A. Phosphorylated SATB1 is associated with the progression and prognosis of glioma. Cell Death Dis. 2013;4:e901.
47. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420–1428.
48. Thiery JP, Acloque H, Huang RYJ. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871–890.
49. Kemler R. From cadherins to catenins: cytoplasmic protein interactions and regulation of cell adhesion. Trends Genet. 1993;9(9):317–321.
50. Bienz M. β-Catenin: a pivot between cell adhesion and Wnt signaling. Curr Biol. 2005;15(2):R64–R67.
51. Yook JI, Li XY, Ota I, et al. A Wnt-Axin2-GSK3β cascade regulates Snail1 activity in breast cancer cells. Nat Cell Biol. 2006;8(12):1398–1406.
52. Hay ED, Zuk A. Transformations between epithelium and mesenchyme: normal, pathological, and experimentally induced. Am J Kidney Dis. 1995;26(4):678–690.
53. Raymond WA, Leong AS. Vimentin – a new prognostic parameter in breast carcinoma? J Pathol. 1989;158(2):107–114.
54. Frömberg A, Rabe M, Aigner A. Multiple effects of the special AT-rich binding protein 1 (SATB1) in colon carcinoma. Int J Cancer. 2014;135(11):2537–2546.
55. Clevers H. Wnt/β-catenin signaling in development and disease. Cell. 2006;149(6):1192–1205.
56. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and β-catenin signaling: diseases and therapies. Nat Rev Genet. 2004;5(9):691–701.
57. Teissedre B, Pinderhughes A, Incassati A, Hatsell SJ, Hiremath M, Cowin P. MMTV-Wnt1 and -ΔN89β-catenin induce canonical signaling in distinct progenitors and differentially activate Hedgehog signaling within mammary tumors. PLoS One. 2009;4:e4537.
58. Ayyanan A, Civenni G, Ciarloni L, et al. Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a notch-dependent mechanism. Proc Natl Acad Sci U S A. 2006;103(10):3799–3804.
59. Savarese F, Davila A, Nechanitzky R, et al. Satb1 and Satb2 regulate embryonic stem cell differentiation and Nanog expression. Genes Dev. 2009;23(22):2625–2638.
60. Ma C, Zhang J, Durrin LK, et al. The BCL2 major breakpoint region (mbr) regulates gene expression. Oncogene. 2007;26(18):2649–2657.
61. Li Q, Dashwood WM, Zhong X, Nakagama H, Dashwood RH. Bcl-2 overexpression in PhIP-induced colon tumors: cloning of the rat Bcl-2 promoter and characterization of a pathway involving β-catenin, c-Myc and E2F1. Oncogene. 2007;26(42):6194–6202.